Cefiderocol in the Treatment of Multidrug-resistant Gram-negative Bacilli Infections, a Retrospective Study

NCT05544682•University Hospital, Strasbourg, France

Summary

Cefiderocol is a new antibiotic from the siderophore cephalosporin family for which there are few real-life data on its use in the treatment of infections with multidrug-resistant Gram-negative bacilli. The circulation of bacterial strains multi-resistant to antibiotics is important at the Strasbourg University Hospital, so the investigators wish to report their local experience of the 1st uses of Cefiderocol in the treatment of infections with multi-resistant Gram-negative bacilli to antibiotics in order to better clarify the use of this antibiotic (therapeutic indication, method of administration)

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patient (≥18 years old)
•taken care of in the HUS and treated as part of routine care with Cefiderocol between 04/01/2020 and 08/31/2022.
•Subjects who have not expressed their opposition to the reuse of their data for scientific research purposes.

Exclusion Criteria

•\- Patient who has expressed his opposition to the retrospective reuse of his data for scientific research purposes.

Locations (1)

Service des maladies infectieuses et tropicales - CHU de Strasbourg - France

Strasbourg, France

Key Dates

Start Date

September 1, 2022

Primary Completion Date

December 1, 2023

Completion Date

December 1, 2023

Last Updated

December 19, 2023

Enrollment

ESTIMATED participants

Conditions

Multidrug Resistant Bacterial Infection

Contacts

Yvon RUCH, MD

CONTACT

33 3 69 55 05 45 yvon.ruch@chru-strasbourg.fr

PMT for MDRO Decolonization

NCT05632315

Multidrug Resistant Bacterial InfectionEnterobacteriaceae Infections+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions